Compare Dyne Therapeutics Inc. Common Stock (DYN) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs KB Financial Group, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while KB Financial Group, Inc. trades at $115.32 (market cap $42.72B). The key difference: KB Financial Group, Inc. is far larger — about 14.9× Dyne Therapeutics Inc. Common Stock's market cap, and KB Financial Group, Inc. pays a 2.73% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and KB Financial Group, Inc. for 33 Days on average.
| DYN | KB | |
|---|---|---|
Market Cap | $2.86B | $42.72B |
Volume | 3,341,579 | 268,131 |
Sector | Health | Financials |
52-Week High | $26.78 | $132.88 |
52-Week Low | $14.60 | $80.15 |
Typical Hold Time | 0 Days | 33 Days |
Enterprise Value | $2.18B | $214.27T |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
KB Financial Group (KB) trades at $117.00, down 4.08% on the day, with bearish technical signals from moving averages. Fundamentally, the company shows strong profitability with 28.09% net income margin and consistent earnings beats, though valuation metrics like P/E of 9.65 suggest potential undervaluation. Recent news highlights institutional interest and positive momentum coverage from financial media.
The stock presents a value opportunity with attractive valuation ratios and solid earnings growth, but faces near-term technical headwinds and mixed analyst sentiment. Key risks include market volatility and execution challenges in the competitive banking sector, while institutional accumulation and strong South Korean market performance provide supportive tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
